USANA HEALTH SCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
USANA HEALTH SCIENCES, INC. (USNA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $70.75 per share for the 12-month period ending 2019-12-28, per its 10-K filed 2020-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2020-02-25
- USANA HEALTH SCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-04-04 was $43.83, a 60.37% increase year-over-year.
- USANA HEALTH SCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2014-03-29 was $27.33.
- USANA HEALTH SCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $70.75, a 8.90% increase from fiscal 2018.
- USANA HEALTH SCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $64.97, a 16.48% increase from fiscal 2017.
- USANA HEALTH SCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2017 was $55.78, a 3.91% decline from fiscal 2016.
- USANA HEALTH SCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $58.05, a 43.16% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2019-12-28 | $70.75 10-K · filed 2020-02-25 | |||
| 2018-12-29 | $64.97 10-K · filed 2019-02-26 | |||
| 2017-12-30 | $55.78 10-K · filed 2018-02-28 | |||
| 2016-12-31 | $58.05 10-K · filed 2017-03-01 | |||
| 2016-01-02 | $102.12 10-K · filed 2016-03-01 | |||
| 2015-10-03 | $43.83 10-Q · filed 2015-11-12 | |||
| 2015-07-04 | $43.83 10-Q · filed 2015-08-12 | |||
| 2015-04-04 | $43.83 10-Q · filed 2015-05-13 | |||
| 2015-01-03 | $49.01 10-K · filed 2015-03-17 | |||
| 2014-09-27 | $37.25 10-Q · filed 2014-11-06 | |||
| 2014-06-28 | $27.33 10-Q · filed 2014-08-05 | |||
| 2014-03-29 | $27.33 10-Q · filed 2014-05-07 | |||
| 2013-12-28 | $35.87 10-K · filed 2014-03-13 | |||
| 2012-12-29 | $29.95 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |